ARTICLE | Finance
Bad language
How investors view Biogen after its anti-LINGO came up short in MS
June 13, 2016 7:00 AM UTC
The loss of more than $8 billion of market cap by Biogen Inc. following the Phase II failure of opicinumab (BIIB033) reflects at least two drivers. Investors are dramatically discounting what they previously thought could be blockbuster potential for the multiple sclerosis candidate. And they are abandoning ship because there is little else to be excited about until 2018.
The big biotech ended Friday with a valuation of $53.9 billion...